The study includes 76 patients who are currently receiving statin therapy and are experiencing myalgias in two or more extremities. They are randomly placed in either a placebo condition or a CoQ10 supplementation condition for three months. Pain questionnaires and visual analog scale (VAS) for assessment of pain intensity are completed at baseline and at monthly visits. The patient’s experience no comparable benefits by taking CoQ10 supplements twice daily. At 1 month, scores in both conditions drop but are not significantly different from each other. The results demonstrate that CoQ10 is not more effective in treating presumed statin-induced myalgias than the placebo. The significant decline in pain measurement at 1 month in both groups is considered a large placebo effect. This article is extremely relevant to the research question as it provides support for the inefficiency or insufficiency of CoQ10 supplements at treating statin-induced myalgia. The scientific evidence in this article clearly supports the uselessness of this nutritional supplement. However, there are a few limitations of this study. Firstly, it is presumed that the muscle pain is due to statin medications. There could be other possible reasons for the causality of patients’ myalgias, which are not explored in this study. Secondly, the diet of the participants was not controlled for. The differences in individual food consumption might affect CoQ10 levels. Thirdly, it is possible that the duration of this study was not long enough and the sample size was not large enough. However, being a fairly recent study it is highly valuable for guiding future
The study includes 76 patients who are currently receiving statin therapy and are experiencing myalgias in two or more extremities. They are randomly placed in either a placebo condition or a CoQ10 supplementation condition for three months. Pain questionnaires and visual analog scale (VAS) for assessment of pain intensity are completed at baseline and at monthly visits. The patient’s experience no comparable benefits by taking CoQ10 supplements twice daily. At 1 month, scores in both conditions drop but are not significantly different from each other. The results demonstrate that CoQ10 is not more effective in treating presumed statin-induced myalgias than the placebo. The significant decline in pain measurement at 1 month in both groups is considered a large placebo effect. This article is extremely relevant to the research question as it provides support for the inefficiency or insufficiency of CoQ10 supplements at treating statin-induced myalgia. The scientific evidence in this article clearly supports the uselessness of this nutritional supplement. However, there are a few limitations of this study. Firstly, it is presumed that the muscle pain is due to statin medications. There could be other possible reasons for the causality of patients’ myalgias, which are not explored in this study. Secondly, the diet of the participants was not controlled for. The differences in individual food consumption might affect CoQ10 levels. Thirdly, it is possible that the duration of this study was not long enough and the sample size was not large enough. However, being a fairly recent study it is highly valuable for guiding future